Aclarion (NASDAQ:ACON) vs. SeaStar Medical (NASDAQ:ICU) Head to Head Comparison

Aclarion (NASDAQ:ACON) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Aclarion and SeaStar Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	1	0	2.00
SeaStar Medical	1	0	1	0	2.00

Aclarion currently has a consensus target price of $7.50, indicating a potential upside of 128.66%. SeaStar Medical has a consensus target price of $8.00, indicating a potential upside of 115.63%. Given Aclarion’s higher probable upside, research analysts plainly believe Aclarion is more favorable than SeaStar Medical.

Institutional & Insider Ownership

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are owned by institutional investors. 0.8% of Aclarion shares are owned by company insiders. Comparatively, 0.7% of SeaStar Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Aclarion and SeaStar Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
SeaStar Medical	-828.62%	-146.29%	-96.48%

Risk & Volatility

Aclarion has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.04, indicating that its stock price is 204% less volatile than the S&P 500.

Valuation & Earnings

This table compares Aclarion and SeaStar Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$77,879.00	103.69	-$7.23 million	($9.03)	-0.36
SeaStar Medical	$1.44 million	10.33	-$12.15 million	($4.80)	-0.77

Aclarion has higher earnings, but lower revenue than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Summary

Aclarion beats SeaStar Medical on 9 of the 12 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.